Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
Raffi
François
F
Lewden
Charlotte
C
Chêne
Geneviève
G
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000150:complications / Q000209:etiology / Q000401:mortality*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D015999:Multivariate Analysis; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine